Brief Healthcare: Sinopharm Group (1099 HK) – Downgrade to a Sell and more
In this briefing: Sinopharm Group (1099 HK) – Downgrade to a Sell Primer: Ptl Enterprises (PTLE IN) - Dec 2025 Mandi Pre-IPO Tearsheet Primer: Kalbe Farma (KLBF IJ) - Dec 2025 Pre-IPO Mandi Inc. - The Business Model, the Concerns and the Valuation 1. Sinopharm Group (1099 HK) – Downgrade to a Sell We expected growth to improve, however, on the contrary growth has slowed, and there seem to be limited short to medium term positive catalysts. Pricing pressure is still a problem, and competition is intense especially in the fragmented medical device market. Given the relatively low growth outlook, and the fact that Sinopharm is largely a distribution model, we see limited opportunity for the company to re-rate from the current level. 2. Primer: Ptl Enterprises (PTLE IN) - Dec 2025 PTL Enterprises operates a unique, low-risk business model, leasing its tyre manufacturing plant in Kerala to its associate company, Apollo Tyres Ltd., generating a stable and predictable rental income stream. The company is characterized by its high dividend yield and attractive valuation, trading at a significant discount to its book value.